Increasing Medical Marijuana and Cannabidiol Research (Trump EO Tracker)

This order directs the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act. Schedule III drugs are classified as having a potential for abuse less than those drugs in Schedules I and II, a currently accepted medical use in treatment in the United States, and a potential for moderate or low physical dependence or high psychological dependence in the event of drug abuse.

Suspends entry for foreign nationals of additional countries of concern from those previously restricted under Proclamation 10949, as determined by the Secretary of State, the Secretary of Homeland Security, the Attorney General, and the Director of National Intelligence. Additional countries include full suspension of entry for Burkina Faso, Laos, Mali, Niger, Sierra Leone, South Sudan, Syria, Palestinian Authority Documents, and partial suspension of entry for Angola, Antigua and Barbuda, Benin, Cote d ‘Ivoire, Dominica, Gabon, the Gambia, Malawi, Mauritania, Nigeria, Senegal, Tanzania, Tonga, Turkmenistan, Zambia, and Zimbabwe.

Designates illicit fentanyl and its core precursor chemicals as Weapons of Mass Destruction (WMD) and directs the use of national security, criminal, sanctions, intelligence, and military-support authorities to combat fentanyl trafficking. Expands enforcement tools against cartels and foreign terrorist organizations involved in fentanyl production and distributions.

Directs the Securities and Exchange Commission (SEC), Federal Trade Commission (FTC), Department of Justice (DOJ), and Department of Labor (DOL) to increase oversight of foreign-owned proxy advisory firms that influence shareholder voting across U.S. public companies. Seeks to curb politically motivated proxy recommendations, particularly those involving diversity, equity, and inclusion (DEI) and environmental, social, and governance (ESG) agendas, by revising SEC rules, strengthening fiduciary standards, and pursuing potential antitrust or consumer-protection violations.